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OUTCOMES FOLLOWING FIRST-TIME LOWER EXTREMITY 
REVASCULARIZATION BETWEEN PATIENTS WITH AND WITHOUT 
DIABETES 
 
 
JEREMY D. DARLING 
 
ABSTRACT 
OBJECTIVES:  Data on the effect of diabetes type (insulin-dependent vs. noninsulin- 
dependent) on short- and long-term outcomes after lower extremity revascularization for 
chronic limb-threatening ischemia (CLTI) are lacking. We sought to address this paucity 
of information by evaluating outcomes in patients with insulin-dependent and noninsulin-
dependent diabetes after first-time bypass and endovascular interventions. 
METHODS: We reviewed all limbs undergoing a first-time infrainguinal bypass (BPG) 
or percutaneous transluminal angioplasty with or without stent (PTA/S) for CLTI at our 
institution from 2005-2014. Based on preoperative medication regimen, patients were 
categorized as having insulin-dependent diabetes (IDDM), noninsulin-dependent diabetes 
(NIDDM), or no diabetes (NDM). Outcomes included wound healing, major amputation, 
RAS events (revascularization, major amputation, or stenosis), major adverse limb events 
(MALE), and mortality. Outcomes were evaluated using Chi-square, Kaplan-Meier, and 
Cox regression analyses. 
RESULTS: Of 2,869 infrainguinal revascularizations from 2005-2014, 1,294 limbs (646 
BPG, 648 PTA/S) fit our criteria and underwent a first-time revascularization for CLTI. 
Overall, 703 IDDM, 262 NIDDM, and 329 NDM limbs were included in our analysis. 
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IDDM patients, compared to NIDDM and NDM, were younger (69 vs. 73 vs. 77 years; 
P<.001) and more often presented with tissue loss (89% vs. 77% vs. 67%; P<.001), 
coronary artery disease (57% vs. 48% vs. 43% P<.001), and end-stage renal disease (26% 
vs. 13% vs. 12%; P<.001). Perioperative complications, including mortality (3% vs. 2% 
vs. 5%; P=.07), did not differ between the three groups; however, complete wound 
healing at 6-month follow-up was significantly worse among IDDM patients (36% vs. 
40% vs. 51%; P<.001). Irrespective of intervention type, IDDM patients had significantly 
higher three-year major amputation rates (BPG: 24% vs. 16% vs. 10%, P=.04; PTA/S: 
21% vs. 6% vs. 5%, P<.001). Multivariable analyses illustrated that, compared to NDM, 
IDDM was associated with significantly higher risk of both major amputation and RAS 
events following any first-time intervention (Hazard Ratio (HR) 2.5, 95% Confidence 
Interval [CI] 1.2-5.2 and 1.4 [1.1-1.9], respectively). Similar associations were found for 
a PTA/S-first intervention (3.1 [1.1-9.0] and 1.5 [1.1-2.2], respectively), while IDDM 
patients undergoing a BPG-first intervention were only associated with incomplete 
wound healing (1.5 [1.3-2.9]). Lastly, when compared to NDM, NIDDM was associated 
with lower late mortality (0.6 [0.5-0.8]). 
CONCLUSIONS:  As compared to NDM, IDDM was associated with similar 
perioperative and long-term mortality but a higher risk of incomplete wound healing, 
major amputation, and future RAS events, especially after a PTA/S-first approach. 
Interestingly, NIDDM was associated with lower long-term mortality and not associated 
with any adverse limb events. Overall, these data demonstrate both the importance in 
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distinguishing between diabetes types, as well as potential long-term benefit of a BPG-
first strategy in appropriately selected IDDM patients with CLTI. 
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INTRODUCTION 	  
The Diabetes Epidemic and Peripheral Arterial Disease (PAD) 
 Diabetes Mellitus (DM) is a chronic illness with substantial financial and health 
implications, rising to epidemic heights in the United States and affecting over 29 million 
individuals in 2012 – a large proportion of whom (over 8 million) were undiagnosed 
(American Diabetes Association [ADA] Statistics About Diabetes, 2016). To elevate 
concerns, the Centers for Disease Control and Prevention (CDC) has recently illustrated 
an alarming trend: From 1980 to 2014, the number of U.S. adults diagnosed with diabetes 
(18 years or older) has nearly quadrupled, from over 5 million to almost 22 million 
(Centers for Disease Control and Prevention [CDC], 2015) (Figure 1). In 2012 alone, the 
direct medical costs associated with diagnosed diabetes were $176 billion – over two-
times higher than healthcare costs associated with non-diabetic medical care (CDC, 
National Diabetes Statistic Report, 2014). 
 
Figure 1: The number of U.S. 
adults aged 18 years or older 
diagnosed with diabetes has 
continued to dramatically 
increase, from approximately 5 
million in 1980 to almost 22 
million by 2014. This alarming 
trend has tremendous health 
and financial consequences 
that show few signs of 
mitigation (CDC, Number (in 
Millions) of Civilian, Non-
Institutionalized Persons with 
Diagnosed Diabetes, 2015). 
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One of the most salient concerns with the common diabetes pathogenesis is the 
propensity for those afflicted to develop varied vascular and neuropathic complications 
that decrease quality of life. Of huge importance is the strong association between 
diabetes and peripheral arterial disease (PAD): According to the National Health and 
Nutrition Examination Survey, 11% of diabetics also had PAD, while only 4% of non-
diabetics had concomitant PAD (Pande, Perlstein, Beckman, & Creager, 2011; Selvin & 
Erlinger, 2004). Defined as atherosclerotic occlusive disease of the lower extremities, 
PAD is associated with increased risk of lower extremity amputation and is a marker for 
cardiovascular bed atherothrombosis, predisposing those afflicted to higher rates of 
myocardial infarction, stroke, and death (Thiruvoipati, Kielhorn, & Armstrong, 2015). 
PAD has been shown to be an independent risk factor for developing ulceration and has 
been noted to be present in up to 50% of foot ulcer patients (Prompers et al., 2007). 
Further, the presence of PAD slows (or entirely halts) ulcer-healing time, is associated 
with greater morbidity and mortality, and is more likely to lead to amputation 
(Brownrigg, Schaper, & Hinchliffe, 2015). Likewise, as recently illustrated by Mueller et 
al. in 2014, among PAD patients 75 years old or younger, five-year mortality rates 
between those with and without diabetes were 23% and 10%, respectively, with those 
percentages increasing to 52% and 37% in PAD patients over 75 (Mueller et al., 2014). 
Despite advances in the management of diabetes, the profound effect of the 
estimated growth is still likely to yield a tremendous escalation in end-stage PAD 
(Fonseca, Kirkman, Darsow, & Ratner, 2012). Importantly, the diagnosis of PAD in 
patients with diabetes is often delayed due to presence of neuropathy, as PAD-related 
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symptoms go unnoticed until more severe symptoms develop (Brownrigg et al., 2015). 
Given the prevalence and severity of such events, non-operative wound management and 
care may not be sufficient to avoid limb loss.  
 
Chronic Limb-Threatening Ischemia (CLTI) and Treatment Options 
Chronic limb ischemia (CLTI), broadly defined as an advanced stage of PAD and 
commonly demarcated by lower extremity rest pain and/or ischemic ulcer or gangrene, is 
significantly more likely in diabetics and is often a refractory condition, secondary to 
diabetes (Katwal & Dokun, 2011). As mentioned, when non-operative management for 
wound prevention and/or wound healing does not produce satisfactory results, surgical 
methods are most commonly utilized, of which there are currently two main treatments 
available: open surgical bypass (BPG) and percutaneous transluminal angioplasty with or 
without stenting (PTA/S). BPG, promoted for its long-term anatomical patency and 
clinical durability, is thought to come at the cost of higher morbidity and substantial 
resource use (Albers, Romiti, Brochado-Neto, & Pereira, 2005; Hobbs et al., 2005). 
Further, the use of autologous vein in BPG procedures may compound wound healing 
issues and further challenge suitable treatment in diabetic, PAD, and CLTI-burdened 
populations (Schaper et al., 2012). Proponents of PTA/S, on the other hand, point to the 
advantages of lower procedural morbidity and mortality, reduced costs, faster procedural 
times, and a shortened hospital stay; however, several studies have illustrated higher rates 
of failure, as compared to BPG (Darling et al., 2017; Joels et al., 2008; Lipsitz et al., 
2004; Papavassiliou, Walker, Bolia, Fishwick, & London, 2003). 
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Ultimately, several studies have compared the utility of both BPG and PTA/S in 
varying degrees of lower extremity limb ischemia and in patients with and without 
diabetes; however, in the current endovascular era, few studies have evaluated the degree 
to which diabetes type – more specifically insulin-dependence and noninsulin-
dependence – may affect long-term outcomes following these revascularization strategies 
(Atar et al., 2005; Clair et al., 2005; Desgranges et al., 2004; Saketkhoo et al., 2004; 
Salas, Adam, Papavassiliou, & London, 2004; Surowiec et al., 2005; Tefera, Hoch, & 
Turnipseed, 2005; Treiman, 2004; Trocciola et al., 2005). Therefore, in this study, we 
sought to describe our institution’s long-term experience with BPG-first and PTA/S-first 
repair in insulin-dependent, noninsulin-dependent, and non-diabetic patients. 
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SPECIFIC AIMS 
Specific aims of the following thesis include: 
1. Review of relevant literature to elaborate on the nature, extent, and relationship of and 
between diabetes type, PAD, and CLTI, depicting the importance in evaluating the most 
efficacious treatment option(s) 
 
2. Elucidation on short- and long-term adverse outcomes among diabetes type in an 
important and prevalent subset of vascular patients (patients with PAD and CLTI) 
 
3. Conclusion on the degree to which diabetes type (insulin-dependent, noninsulin-
dependent, no diabetes) differs in regards to the short- and long-term effects following 
specific first-time revascularization strategies (i.e., BPG and PTA/S)  
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METHODS 
 
Subjects and settings 
We performed a retrospective review of all patients with CLTI undergoing a first-
time lower extremity intervention at Beth Israel Deaconess Medical Center (BIDMC). 
Medical records of all BPG and PTA/S interventions from January 2005 to October 2014 
were individually reviewed. Patients were categorized as having insulin-dependent 
diabetes (IDDM), noninsulin-dependent diabetes (NIDDM), or no diabetes (NDM). 
IDDM was defined as preoperative or at-home reliance on insulin administration to 
control diabetes at baseline. Patients with diabetes who were not prescribed insulin were 
categorized as having NIDDM. Importantly, for the purposes of this study, insulin 
dependence is not considered tantamount to type I diabetes, as it describes the patient-
level pattern of insulin use at the time of revascularization. Patients who received 
previous interventions on the ipsilateral limb (whether at BIDMC or at an outside 
institution) or interventions at or proximal to the iliac arteries were excluded. Patients 
undergoing a concomitant procedure, including endarterectomy, profundaplasty, 
thrombectomy, atherectomy, or patch, were included and adjusted for in our analyses. 
Interval and modality for typical patient follow-up was every 3 to 4 months for 2 years 
and every 6 months afterwards, with arterial duplex ultrasound imaging and ankle-
brachial indices with forefoot pulse volume recordings and/or toe pressures.  
Our analysis included patients whose disease severity was distinctly classifiable 
as CLTI and who underwent either a first-time BPG or a first-time PTA/S. Indications for 
intervention included tissue loss (i.e., gangrene and ulcer) or rest pain. Patients presenting 
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with more than one indication were assigned hierarchically, with gangrene constituting as 
the most severe indication, followed by ulcer, and, lastly, rest pain. Femoropopliteal 
lesion anatomy and severity were defined according to the modified Trans Atlantic Inter-
society Consensus (TASC II) classification. As there was no updated TASC class for 
tibial lesions included in the modified TASC II classification, tibial lesion information 
was defined by TASC I (Dormandy & Rutherford, 2000; Norgren et al., 2007). 
 
Measurements and outcome variables 
Primary outcomes included perioperative complications, wound healing, major 
amputation, RAS events (a composite variable denoted by re-intervention, major 
amputation, or stenosis), major adverse limb events (MALE, a composite variable 
denoted by any major amputation or any major re-intervention, defined as creation of a 
new bypass graft, a jump graft revision, surgical thrombectomy with or without surgical 
patch angioplasty, and thrombectomy of an occluded graft or arterial segment using 
pharmacologic or mechanical thrombolysis), and mortality (Conte, 2010). Demographics, 
comorbidities, SVS WIfI information, restenosis, and re-intervention were also recorded 
(Mills et al., 2014). Perioperative complications included hematoma, acute myocardial 
infarction, and death. Criteria for restenosis was at least 75% stenosis by angiographic 
measurement, or a >3.5 fold increase in peak systolic velocity by duplex. Re-
interventions included any ipsilateral surgical or endovascular revision and were most 
commonly performed for symptomatic graft restenosis or threatened asymptomatic grafts 
(peak systolic velocity ratio >3.5–4 or low graft velocities <30cm/second). Ordinarily, 
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patients did not undergo re-interventions for an asymptomatic restenosis after PTA alone; 
however, attending physicians were more likely to re-intervene with PTA/S for an 
asymptomatic in-stent restenosis if the peak systolic velocity ratio was >3.5–4. Type of 
re-intervention strategy was surgeon-dependent and varied over time with the acquisition 
of endovascular skills: Generally, PTA/S-first strategies were done so at the clinical 
judgment of the attending physician at the time of the angiogram. Routine statin use was 
introduced over time, and PTA/S patients were generally discharged on clopidogrel for 
one month post-operatively and aspirin indefinitely. Technical success following PTA/S 
was defined as less than 30% residual stenosis and no flow-limiting dissection, while 
technical success following BPG included a patent bypass graft at completion, which was 
defined as one without significant defect in the vein on angioscopy and continuous wave 
Doppler interrogation. 
 
Statistical Analyses 
Contingent on the outcome of interest, analyses were performed on either a per-
limb basis (i.e., wound healing, stenosis, re-intervention, amputation, RAS, MALE) or a 
per-patient basis (i.e., mortality), where, on per-patient outcomes, the initial limb was 
censored at the procedure date of the contralateral limb. Pearson chi-square and Fisher 
exact tests were used for categorical variable comparison. Continuous variables were 
compared using Student t-test or Mann-Whitney U test. Rates were compared across 
strata (IDDM, NIDDM, and NDM) using chi-square analysis. Treatment outcomes 
during the course of follow-up were analyzed using Kaplan-Meier methodology, and 
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unadjusted time-to-failure curves were compared with the log-rank test. Covariates were 
selected using purposeful selection, incorporating backward selection after a univariate 
screen (P < .10) as well as including relevant patient factors previously identified 
(Bursac, Gauss, Williams, & Hosmer, 2008). Multivariable Cox regression models were 
constructed to assess independent associations between diabetes type and time-dependent 
outcomes. Statistical significance was defined as P < .05. All statistical tests were done 
using STATA 13 (StataCorp, College Station, Tex). The Beth Israel Deaconess Medical 
Center Institutional Review Board approved this study and waived the need for patient 
consent. 
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RESULTS 	  
Baseline Characteristics 
Of the 2,869 total lower extremity revascularizations performed between January 
2005 and October 2014, 1,294 limbs in 1,160 patients met our inclusion criteria: 646 
undergoing a primary BPG and 648 undergoing a primary PTA/S. As Figure 2a 
illustrates, the number of IDDM limbs treated with a revascularization gradually 
decreased over the study period (from 84 procedures in 2005 to 58 in 2013), as did the 
number of IDDM limbs treated with a BPG-first approach (from 79% in 2005 to 22% in 
2013). Additionally, as Figure 2b and 2c demonstrate, these decreasing trends remained 
relatively consistent across NIDDM and NDM limbs, with the former undergoing 61% 
BPG-first procedures in 2005 and 26% in 2013 and the latter falling from 71% BPG-first 
interventions to 22%.  
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Figure 2: Number of yearly first-time revascularization procedures performed on patients 
with chronic limb-threatening ischemia and a) insulin-dependent diabetes, b) noninsulin-
dependent diabetes, and c) no diabetes 
 
PTA/S, percutaneous angioplasty with or without stent; IDDM, insulin-dependent diabetes; 
NIDDM, noninsulin-dependent diabetes; NDM, non-diabetes 
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Overall, 703 IDDM, 262 NIDDM, and 329 NDM limbs were included in our 
analysis. IDDM patients, compared to NIDDM and NDM patients, respectively, were 
younger (69 vs. 73 vs. 77 years; P < .001) and more often presented with tissue loss (89% 
vs. 78% vs. 67%; P < .001), coronary artery disease (57% vs. 48% vs. 43% P < .001), and 
end-stage renal disease (26% vs. 13% vs. 12%; P < .001) (Table 1). Conversely, NDM 
patients more commonly suffered from COPD (10% vs. 9% vs. 19%; P < .001) and more 
frequently smoked (57% vs. 58% vs. 69%; P = .001). Groups did not differ in male sex 
(62% vs. 57% vs. 56%; P = .13) or in rates of congestive heart failure (34% vs. 28% vs. 
28%; P = .10). There was no difference in the proportion of patients undergoing a 
primary BPG by diabetes type (49% vs. 51% vs. 52%; P = .58). The prevalence of 
preoperative femoropopliteal TASC D lesions was lowest in IDDM patients (17% vs. 
19% vs. 31%; P < .001), although this difference was not seen when directly comparing 
IDDM to NIDDM (P = .46). There was no difference in tibial TASC D lesions (32% vs. 
29% vs. 32%; P = .69). Finally, WIfI clinical stage 4 was most prevalent among IDDM 
patients (52% vs. 43% vs. 31%; P < .02), potentially driven by the high WIfI wound 
component among these patients (1.6 vs. 1.4 vs. 1.2; P < .01). 
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Table 1: Demographics, co-morbidities, and pre-operative lesion characteristics between 
1,294 patients with insulin-dependent diabetes, noninsulin-dependent diabetes, and no 
diabetes with chronic limb-threatening ischemia (CLTI) 
IDDM, insulin-dependent diabetes; NIDDM, noninsulin-dependent diabetes; NDM, non-diabetes; COPD, chronic 
obstructive pulmonary disease; WIfI, wound, ischemia, and foot infection; TASC, Trans Atlantic Inter-society Consensus 
 
 
 
 
IDDM NIDDM NDM
(N=703) (N=262) (N=329)
Demographics No. (%)
    Age, mean (SD) 68.9 (12.0) 72.9 (11.0) 76.6 (12.5) <.001 <.001 <.001 <.001
    Race 0.03 <.001 0.04 <.001
        White 518 (74) 210 (81) 286 (87)
        Non-white 182 (26) 50 (19) 43 (13)
    Male sex 436 (62) 148 (57) 185 (56) .13 .08 .91 .13
Indication, No. (%)     
    Rest Pain 78 (11) 59 (23) 108 (33) <.001 <.001 <.01 <.001
    Ulcer 407 (58) 124 (47) 148 (45) <.01 <.001 .57 <.001
    Gangrene 218 (31) 79 (30) 73 (22) .80 <.01 .03 .01
Comorbidities, No. (%)
    Coronary artery disease 395 (57) 123 (48) 136 (43) .01 <.001 .27 <.001
    Hypertension 622 (89) 226 (87) 242 (76) .47 <.001 .001 <.001
    Hyperlipidemia 466 (67) 145 (56) 167 (53) <.01 <.001 .43 <.001
    Dialysis dependence 185 (26) 34 (13) 38 (12) <.001 <.001 .67 <.001
    BMI, mean 29.0 27.6 24.5 <.01 <.001 <.001 .04
    History of myocardial infarction 215 (31) 65 (25) 54 (17) .09 <.001 .02 <.001
    Congestive heart failure 234 (34) 73 (28) 88 (28) .12 .06 .89 .10
    COPD 69 (10) 23 (8.9) 60 (19) .66 <.001 .001 <.001
    Smoking history 401 (57) 150 (58) 220 (69) .88 <.001 <.01 .001
WIfI clinical stage,16 No. (%)
    Clinical stage 1 6 (1.2) 2 (1.0) 3 (1.2) .85 .98 .85 .98
    Clinical stage 2 99 (19) 65 (33) 116 (46) <.001 <.001 <.01 <.001
    Clinical stage 3 140 (27) 48 (24) 56 (22) .37 .13 .66 .28
    Clinical stage 4 268 (52) 85 (43) 77 (31) .02 <.001 <.01 <.001
Fempop TASC classification, No. (%)
    TASC A 120 (19) 50 (22) 42 (15) .49 .11 .05 .13
    TASC B 185 (30) 78 (34) 82 (29) .30 .83 .28 .50
    TASC C 76 (12) 30 (13) 44 (16) .80 .17 .38 .38
    TASC D 104 (17) 44 (19) 88 (31) .46 <.001 .001 <.001
Tibial TASC classification, No. (%)
    TASC A 78 (13) 30 (13) 35 (13) .83 .97 .87 .98
    TASC B 143 (23) 46 (20) 55 (20) .36 .29 .95 .46
    TASC C 138 (23) 50 (21) 55 (20) .91 .43 .58 .72
    TASC D 198 (32) 66 (29) 87 (32) .40 .89 .53 .70
P-value         
(IDDM to 
NIDDM)
P-value         
(IDDM to 
NDM)
P-value         
(NIDDM to 
NDM)
P-value         
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Of the 646 BPG-first procedures, the femoral artery was the most common inflow 
artery (74% of all procedures), although significantly less so among IDDM patients (68% 
vs. 74% vs. 84%; P = .001). When directly comparing IDDM to NDM, the outflow artery 
among IDDM patients was less commonly the popliteal artery (29% vs. 40%; P = .01) 
and was more commonly the dorsalis pedis/pedal arteries (29% vs. 16%; P < .01) (Table 
2). Procedural details were not significantly different between IDDM and NIDDM 
patients nor between NIDDM and NDM patients. Single-segment great saphenous vein 
conduits were used in over three-quarters of procedures performed in each group (76% 
vs. 80% vs. 78%; P = .56), where non-reversed great saphenous vein was most the most 
common conduit (40% vs. 41% vs. 39%; P = .88). Composite vein conduit use (6% vs. 
5% vs. 8%; P = .49) and synthetic conduit use (12% vs. 12% vs. 12%; P = .98) did not 
differ between diabetes type. 
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Table 2: Operative details of 646 insulin-dependent, noninsulin-dependent, and non-
diabetic patients undergoing open surgical bypass for chronic limb-threatening ischemia 
(CLTI)           
 
 IDDM, insulin-dependent diabetes; NIDDM, noninsulin-dependent diabetes; NDM, non-diabetes 
 
 
 
 
 
 
 
 
 
 
 
 
 
IDDM NIDDM NDM
(N=342) (N=133) (N=171)
Inflow artery, No. (%)
    Femoral 233 (68) 99 (74) 143 (84) .18 <.001 .049 .001
    Popliteal 109 (32) 34 (26) 27 (16) .18 <.001 .04 <.001
    Tibial 1 (0.6) 0 (0) 0 (0) .16 .38 - .25
Outflow artery, No. (%)
    Popliteal 98 (29) 45 (34) 69 (40) .27 .01 .29 .04
    Tibial 126 (37) 41 (31) 56 (33) .16 .27 .73 .29
    Peroneal 21 (6.1) 13 (10) 18 (11) .33 .10 .66 .25
    Dorsalis pedis/pedal 98 (29) 33 (24) 28 (16) .26 <.01 .10 <.01
Conduit, No. (%)
    In situ saphenous vein 76 (22) 29 (22) 45 (26) .92 .30 .36 .53
    Reversed saphenous vein 41 (12) 21 (16) 21 (12) .27 .92 .38 .52
    Non-reversed saphenous vein 138 (40) 55 (41) 66 (39) .84 .70 .63 .88
    Arm vein 36 (11) 9 (6.8) 13 (7.7) .21 .29 .78 .34
    Composite vein 19 (5.6) 6 (4.5) 13 (7.7) .65 .37 .27 .49
    Synthetic 42 (12) 16 (12) 20 (12) .95 .85 .92 .98
P-value
P-value         
(IDDM to 
NIDDM)
P-value         
(IDDM to 
NDM)
P-value         
(NIDDM to 
NDM)
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Finally, of the 648 PTA/S-first procedures, IDDM patients were less likely to 
undergo a superficial femoral artery angioplasty (57% vs. 67% vs. 75%; P < .001) and 
were more likely to undergo an anterior tibial angioplasty (31% vs. 11% vs. 16%; P < 
.001) (Table 3). Further, there were no differences in multi-level interventions (42% vs. 
42% vs. 49%; P = .34); however, femoropopliteal stenting was significantly less common 
among IDDM patients (26% vs. 31% vs. 42%; P = .001) – a significant difference that 
was most likely driven by the difference between IDDM patients and NDM patients (P < 
.001). NIDDM patients, when compared solely to NDM patients, were significantly less 
likely to undergo infrapopliteal stenting (3% vs. 9%; P = .045). 
The median follow-up for IDDM, NIDDM, and NDM patients was 1.5 years 
(range <1–10), 1.6 years (<1–10), and 1.3 years (<1–10), respectively. 
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Table 3: Operative details of 648 insulin-dependent, noninsulin-dependent, and non-
diabetic patients undergoing percutaneous transluminal angioplasty for chronic limb-
threatening ischemia (CLTI) 
  IDDM, insulin-dependent diabetes; NIDDM, noninsulin-dependent diabetes; NDM, non-diabetes 
 
 
 
 
 
 
 
 
 	  
 
 	  	  	  
IDDM NIDDM NDM
(N=342) (N=133) (N=171)
Proximal vessel, No. (%)
    Femoral 204 (57) 86 (67) 118 (75) .04 <.001 .14 <.001
    Popliteal 126 (35) 44 (34) 69 (44) .87 .06 .10 .13
Infrapopliteal vessel, No. (%)
    Anterior tibial 111 (31) 14 (11) 25 (16) <.001 <.001 .22 <.001
    Posterior tibial 59 (16) 13 (10) 16 (10) .08 .06 .99 .07
    Peroneal 73 (20) 25 (19) 24 (15) .84 .18 .35 .40
    Dorsalis pedis/pedal 10 (3.0) 0 (0.0) 2 (1.3) .06 .29 .20 .11
    Multi-level (prox + infrapop) 152 (42) 54 (42) 77 (49) .96 .16 .25 .34
Stenting, No. (%)
    Any 109 (30) 43 (33) 71 (45) .51 .001 .046 <.01
    Femoropopliteal 92 (26) 40 (31) 66 (42) .23 <.001 .06 .001
    Infrapopliteal 26 (7.2) 4 (3.1) 14 (8.9) .10 .51 .045 .14
P-value
P-value         
(NIDDM to 
NDM)
P-value         
(IDDM to 
NIDDM)
P-value         
(IDDM to 
NDM)
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Perioperative Outcomes 
 Following any lower extremity revascularization for CLTI, IDDM patients 
exhibited a significantly longer total hospital length of stay (LOS) (9.6 vs. 8.9 vs. 8.0 
days; P < .01), most likely driven by the LOS difference between IDDM and NDM 
patients (P < .001) (Table 4). Further univariate analysis suggested that both 
perioperative mortality (3.0 vs. 1.5 vs. 4.9; P = .07) and perioperative complications 
(15% vs. 12% vs. 15%; P = .60) were similar between groups. Among BPG-first patients, 
perioperative surgical site infections did not differ (11% vs. 10% vs. 8%; P = .52). 
Regardless of procedure type, after adjusting for baseline characteristics, multivariable 
analysis found diabetes type to not be associated with perioperative death or 
complications. 
 
 
 
 
 
 
 
 
 
 
 
	  19 
Table 4: Perioperative outcomes and complications between 1,294 insulin-dependent, 
noninsulin-dependent, and non-diabetic patients with chronic limb-threatening ischemia 
(CLTI) 
 
 IDDM, insulin-dependent diabetes; NIDDM, noninsulin-dependent diabetes; NDM, non-diabetes; LOS, length of stay 
 
 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
IDDM NIDDM NDM
(N=703) (N=262) (N=329)
 Perioperative Outcomes, No. (%)
    Pre-operative LOS, mean days 3.3 3.1 2.4 .39 <.001 .05 <.01
    Post-operative LOS, mean days 6.3 5.8 5.6 .23 .05 .62 .11
    Total LOS, mean days 9.6 8.9 8.0 .22 <.01 .14 <.01
    Hematoma 40 (5.7) 15 (5.7) 20 (6.1) .98 .80 .86 .97
    Acute myocardial infarction 13 (1.8) 1 (0.4) 4 (1.2) .09 .46 .27 .21
    Mortality 21 (3.0) 4 (1.5) 16 (4.9) .20 .13 .03 .07
P-value         
(IDDM to 
NIDDM)
P-value         
(IDDM to 
NDM)
P-value         
(NIDDM to 
NDM)
P-value         
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Long-term Outcomes 
Unadjusted Kaplan-Meier analysis demonstrated that complete wound healing at 
6-month follow-up was significantly worse among IDDM patients (36% vs. 40% vs. 
51%; P < .001). Further unadjusted Kaplan-Meier analyses illustrated no significant 
difference in three-year rates of restenosis (50% vs. 46% vs. 38%; P = .36) and re-
intervention (36% vs. 37% vs. 31%; P = .63) but did demonstrate significant differences 
in three-year rates of major amputation (23% vs. 11% vs. 8%; P < .001; Figure 3), RAS 
events (65% vs. 55% vs. 51%; P = .04; Figure 4), MALE (34% vs. 27% vs. 23%; P < 
.01; Figure 5), and death (44% vs. 35% vs. 49%; P < .01; Figure 6). 
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Figure 3: Unadjusted effect of diabetes type on long-term limb salvage among patients 
undergoing any lower extremity revascularization for chronic limb-threatening ischemia 
(CLTI) 
 
 
         IDDM, insulin-dependent diabetes; NIDDM, noninsulin-dependent diabetes; NDM, non-diabetes; S.E., standard error 
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Figure 4: Unadjusted effect of diabetes type on long-term freedom from re-intervention, 
amputation, or stenosis (RAS) among patients undergoing any lower extremity 
revascularization for chronic limb-threatening ischemia (CLTI) 
 
 
          IDDM, insulin-dependent diabetes; NIDDM, noninsulin-dependent diabetes; NDM, non-diabetes; S.E., standard error 
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Figure 5: Unadjusted effect of diabetes type on long-term freedom from any major 
adverse limb event (MALE) among patients undergoing any lower extremity 
revascularization for chronic limb-threatening ischemia (CLTI) 
 
 
          IDDM, insulin-dependent diabetes; NIDDM, noninsulin-dependent diabetes; NDM, non-diabetes; S.E., standard error 
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Figure 6: Unadjusted effect of diabetes type on long-term survival among patients 
undergoing any lower extremity revascularization for chronic limb-threatening ischemia 
(CLTI) 
 
 
          IDDM, insulin-dependent diabetes; NIDDM, noninsulin-dependent diabetes; NDM, non-diabetes; S.E., standard error 
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After adjustment, among all procedure types, diabetes type was not shown to 
independently affect restenosis or re-intervention. Conversely, among all 
revascularization strategies, with NDM as the reference group, IDDM was shown to 
independently heighten a patient’s risk of incomplete wound healing (Hazard Ratio (HR) 
1.4, 95% Confidence Interval [CI], 1.2-2.9), major amputation (2.4 [1.1-5.1]), RAS 
events (1.4 [1.1-1.9]) and MALE (1.6 [1.1-2.7]) (Table 5). Among BPG-first 
interventions, IDDM patients were shown to only independently heighten the risk of 
incomplete wound healing (1.5 [1.3-2.9]). Finally, among PTA/S-first interventions, 
IDDM patients were shown to independently heighten the risk of incomplete wound 
healing (1.7 [1.3-3.8]), major amputation (3.5 [1.2-10.6]), and RAS events (1.5 [1.1-2.1]). 
NIDDM patients, on the other hand, were not shown to be significantly associated with 
any limb-related primary outcome; however, interestingly, NIDDM, as compared to 
NDM, was associated with a significantly lower risk of mortality among patients 
undergoing any revascularization type (0.6 [0.5-0.8]), a BPG-first intervention (0.6 [0.5-
0.9]), and a PTA/S-first intervention (0.6 [0.4-0.9]). 
An important and final note is that, when combining IDDM and NIDDM patients 
(i.e., comparing 965 diabetic patients vs. 329 non-diabetic patients), multivariable 
analysis demonstrated that any diabetes was significantly associated with higher risk of 
incomplete wound healing (1.4, 1.1-1.9]), major amputation (2.4 [1.2-4.8]), and MALE 
(1.7 [1.1-2.7]), but there was no difference in mortality (0.9 [0.6-1.1]; P = .07). 
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Table 5: Multivariable analyses of diabetes type on long-term major amputation, RAS 
events, and mortality 
 
 
 
 
 
 
 	  
Outcomes HR 95% CI Pvalue HR 95% CI Pvalue HR 95% CI Pvalue
Mortality
   NDM (ref) - - - - - - - - -
   NIDDM 0.6 0.5-0.8 .001 0.6 0.5-0.9 .01 0.6 0.4-0.9 .01
   IDDM 0.9 0.7-1.1 .29 0.9 0.7-1.3 .65 0.8 0.6-1.2 .28
Major amputation
   NDM (ref) - - - - - - - - -
   NIDDM 2.0 0.9-4.9 .23 1.9 0.6-6.2 .28 1.2 0.3-4.5 .76
   IDDM 2.4 1.1-5.1 .01 2.2 0.8-6.6 .15 3.5 1.2-10.6 .03
RAS
   NDM (ref) - - - - - - - - -
   NIDDM 0.9 0.6-1.4 .68 1.1 0.6-2.0 .66 0.8 0.5-1.3 .39
   IDDM 1.4 1.1-1.9 .04 1.5 0.9-2.4 .14 1.5 1.1-2.1 .03
MALE
   NDM (ref) - - - - - - - - -
   NIDDM 1.1 0.6-1.9 .87 0.9 0.5-1.6 .59 1.0 0.4-2.6 .99
   IDDM 2.0 1.1-2.7 .04 1.4 0.8-2.3 .2 1.7 0.8-3.6 .16
Incomplete healing
   NDM (ref) - - - - - - - - -
   NIDDM 1.2 0.7-1.2 .30 1.3 0.8-1.7 .16 1.4 0.6-1.9 .20
   IDDM 1.4 1.2-3.2 <.01 1.5 1.3-2.9 .01 1.7 1.3-3.8 .03
PTA/S-first            
(N=648)
Bypass-first         
(N=646)
Any intervention         
(N=1,294)
NDM, no diabetes; NIDDM, non-insulin-dependent diabetes; IDDM, insulin-dependent diabetes; RAS, re-intervention, amputation, or stenosis;            
HR, hazard ratio; CI, confidence interval; RAS, re-intervention, amputation, or stenosis; MALE, major adverse limb event                                                                                                                                       
Additionally adjusted for age, gender, symptom statu,s ambulatory status, living status, race, renal diseasae, coronary artery disease, hypertension, 
hyperlipidemia, history of myocardial infarction, congestive heart failure, TASC classification, smoking history, COPD, and procedure type                              
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DISCUSSION 
 Our data illustrate that, in patients undergoing a first-time lower extremity 
revascularization for CLTI, those suffering from IDDM present at an earlier age and with 
more severe disease. Regardless of revascularization strategy, there are no differences in 
perioperative complications, restenosis, or re-intervention; however, IDDM was 
associated with longer pre-operative and total hospital lengths of stay, as well as a 
heightened risk of incomplete wound healing, major amputation, RAS events, and major 
adverse limb events. Conversely, NIDDM patients – seemingly the least diseased-burden 
of the three groups – were shown to have lower long-term mortality (compared to NDM), 
even after adjusting for the discrepancy in comorbidity burden. More specifically, as 
compared to NDM patients, IDDM patients undergoing a PTA/S-first strategy were 
shown to have a heightened risk of incomplete wound healing, RAS events, and major 
amputation. Conversely, IDDM patients undergoing a BPG-first strategy were shown to 
only be associated with poorer wound healing, suggesting that the oft-referenced adverse 
outcomes in IDDM patients may be most mitigated following a BPG-first strategy. 
  Prior studies have illustrated that the impact of diabetes on perioperative 
outcomes remains controversial, with several studies demonstrating higher risk of 
perioperative morbidity and mortality among patients with diabetes, whereas others 
report no added risk in this patient population (Akbari et al., 2000; Awad et al., 2006; 
Luther & Lepantalo, 1997; Virkkunen, Heikkinen, Lepantalo, Metsanoja, & Salenius, 
2004). In 2004, Virkkunen et al. studied 5,709 lower extremity bypasses performed for 
CLTI and found that patients with diabetes, although not differing in perioperative 
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mortality, demonstrated a higher risk of wound infection (Odds ratio (OR), 1.3), cardiac 
complications (OR, 1.5), and major amputation (OR, 1.7) (Virkkunen et al., 2004). 
Conversely, Akbari et al. illustrated lower perioperative mortality in patients with 
diabetes (as compared to those without; 0.9% vs. 4.2%), and no difference in five-year 
survival or limb salvage (Akbari et al., 2000). Further, Hamdan et al. – reporting 
perioperative and long-term outcomes among 4,052 lower extremity procedures – also 
found diabetes to be associated with lower perioperative mortality (OR, 0.6) and to 
decrease five-year survival, although these were unadjusted rates and no multivariable 
analysis was performed (Hamdan et al., 2002). Importantly, however, these studies did 
not distinguish between diabetes type, which, as our data illustrate, may play individual 
and important roles in long-term risk. 
 Fortunately, several recent studies have elaborated on the potential importance of 
diabetes type following lower extremity revascularization. In 2007, Hertzer et al. – 
stratifying by diabetes type – examined a single surgeon’s experience with over 600 
lower extremity bypasses for PAD and found no difference in perioperative mortality and 
significantly higher rates of one-year and five-year mortality among NIDDM (1.4 [1.1–
1.8]) and IDDM (1.5 [1.2–1.8]) patients (Hertzer, Bena, & Karafa, 2007). This study also 
demonstrated IDDM to be significantly associated with higher short- and long-term 
amputation (OR, 2.6 and OR, 1.8, respectively). Additionally, in 2012, Wallaert et al. 
analyzed the effect of diabetes type on 1,977 infrainguinal bypass patients with CLTI, 
demonstrating that diabetes type does not significantly affect perioperative mortality rates 
and that both NIDDM and IDDM increase perioperative risk of any major adverse event, 
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a composite variable defined as myocardial infarction, dysrhythmia, congestive heart 
failure, renal insufficiency, wound infection, and major amputation (OR, 1.4 and OR 1.5, 
respectively). Unfortunately, both studies focus only on patients undergoing bypass, 
providing little information regarding a prevalent subset of patients who undergo PTA/S 
procedures.  
 Lastly, in 2007, Dick et al. performed a prospective cohort study of 426 limbs 
suffering from both diabetes and CLTI undergoing conservative treatment, endovascular 
treatment, or surgical treatment (Dick et al., 2007). This study demonstrated that one-year 
clinical success – defined as survival without major amputation or future target extremity 
revascularization – was significantly better in non-diabetic patients (HR, 0.48), and that, 
in both diabetic and non-diabetic patients, this success was not influenced by mode of 
initial revascularization. Further, diabetes was not shown to be significantly associated 
with higher one-year mortality (P = .064). Ultimately, diabetic patients within this cohort 
were shown to improve to the same degree as in non-diabetic patients, but only through 
multiple revascularization procedures and by means of close follow-up and timely 
repetition of target extremity revascularization. 
 Overall, our study both differs from and corroborates previous literature. 
Curiously, NIDDM patients within our study were shown to have lower long-term 
mortality, which is a novel finding compared to prior works. Generally, we believe that 
this outcome may be less reflective of the health of NIDDM patients and more reflective 
of the severity of disease among and between both IDDM and NDM patients, as NIDDM 
patients were less likely to have tissue loss, coronary artery disease, and congestive heart 
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failure (as compared to IDDM), and decreased proportions of COPD, smoking history, 
and femoropopliteal TASC D lesions (as compared to NDM). Although a surprising 
finding, the lower mortality among NIDDM patients may further reflect better – or 
simpler – long-term medical management, or the potential additional increases in cardiac 
risk within the IDDM and NDM patients that is not presently captured within this 
analysis. Importantly, when combining IDDM and NIDDM groups, our study 
substantiates the insignificant differences in long-term mortality that several previous 
studies have demonstrated, further highlighting the importance of evaluating the 
distinction between insulin-dependent and noninsulin-dependent diabetes within CLTI 
patients (Akbari et al., 2000; Awad et al., 2006; Dick et al., 2007; Hertzer et al., 2007). 
 There are important limitations to this study. First, it was a retrospective, single-
center review where patients were allocated to revascularization strategy based on 
surgeon preference, which changed over time. As these data represent the a single-center 
experience, the potential for selection and information bias exists; therefore, our results 
are subject to the influence of specific referral patterns, surgeon experience, and patient 
selection preferences. Second, these data only include patients undergoing 
revascularization attempts and do not reflect outcomes for those patients treated with 
medical management or primary amputation as a contrast. Fortunately, several previously 
published studies have illustrated both the poor outcomes following medical management 
and the importance of revascularization in diabetic patients with CLTI (Awad et al., 
2006; Dick et al., 2007; Faglia et al., 2012; LoGerfo et al., 1992; Luther & Lepantalo, 
1997; Muhs, Gagne, & Sheehan, 2005). Third, information regarding onset of diabetes 
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and diabetes symptoms were difficult to accurately capture within this study and may be 
important to consider in regards to certain differences illustrated between diabetes types – 
perhaps most important noticed in patient age. Lastly, since supplementary measures of 
diabetes disease severity were not readily accessible for this study, including patient 
hemoglobin A1c, baseline insulin reliance and administration was used as a replacement 
for disease severity, which could increase potential for confounding factors. Ultimately, 
however, our data include one of the largest reported analyses of the effect of diabetes 
type on the initial revascularization for CLTI. 
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CONCLUSION 
 To conclude, our data suggest that insulin-dependent patients undergoing any 
first-time revascularization for CLTI may have a disease severity-dependent limb effect 
on a variety of long-term outcomes. Noninsulin dependence is not associated with these 
long-term events and, as compared to non-diabetic patients, is actually associated with 
lower long-term mortality. Overall, these data demonstrate the importance in 
distinguishing between diabetes type, as insulin-dependent, noninsulin-dependent, and 
non-diabetic patients all present with differing degrees of disease and comorbid 
conditions that harbor varying degrees of limb-based and patient-based risk. Finally, 
although insulin-dependence is associated with the greatest risk of adverse outcomes, 
these data suggest that these adversities may be most mitigated in those IDDM patients 
that are appropriately selected and anatomically suitable for a bypass. 
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